share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5：募資說明書
美股sec公告 ·  05/06 09:19
Moomoo AI 已提取核心訊息
Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $20,000,000. This update, detailed in a prospectus supplement filed on May 6, 2024, follows the company's public float surpassing $75.0 million on May 2, 2024, which lifted the previous sales limitation under General Instruction I.B.6 of Form S-3. Prior to this amendment, Allarity Therapeutics was restricted to selling up to $18,000,000 worth of common stock. As of May 2, 2024, the company had already sold 10,835,422 shares for gross proceeds of $16,054,081. The new prospectus supplement allows for the sale of additional shares up to the new $20,000,000 limit, inclusive of the gross proceeds already obtained through the Sales Agreement.
Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $20,000,000. This update, detailed in a prospectus supplement filed on May 6, 2024, follows the company's public float surpassing $75.0 million on May 2, 2024, which lifted the previous sales limitation under General Instruction I.B.6 of Form S-3. Prior to this amendment, Allarity Therapeutics was restricted to selling up to $18,000,000 worth of common stock. As of May 2, 2024, the company had already sold 10,835,422 shares for gross proceeds of $16,054,081. The new prospectus supplement allows for the sale of additional shares up to the new $20,000,000 limit, inclusive of the gross proceeds already obtained through the Sales Agreement.
Allarity Therapeutics Inc.宣佈修訂其與Ascendiant Capital Markets, LLC的銷售協議，將其可能發行和出售的普通股總額增加到2,000萬美元。2024年5月6日提交的招股說明書補充文件詳細介紹了這一更新，此前該公司於2024年5月2日公開持股量超過7,500萬美元，這取消了先前根據S-3表格I.B.6號一般指令規定的銷售限制。在此修正案之前，Allarity Therapeutics僅限於出售價值不超過1800萬美元的普通股。截至2024年5月2日，該公司已經出售了10,835,422股股票，總收益爲16,054,081美元。新的招股說明書補充文件允許在新的20,000,000美元限額內出售額外股份，其中包括通過銷售協議獲得的總收益。
Allarity Therapeutics Inc.宣佈修訂其與Ascendiant Capital Markets, LLC的銷售協議，將其可能發行和出售的普通股總額增加到2,000萬美元。2024年5月6日提交的招股說明書補充文件詳細介紹了這一更新，此前該公司於2024年5月2日公開持股量超過7,500萬美元，這取消了先前根據S-3表格I.B.6號一般指令規定的銷售限制。在此修正案之前，Allarity Therapeutics僅限於出售價值不超過1800萬美元的普通股。截至2024年5月2日，該公司已經出售了10,835,422股股票，總收益爲16,054,081美元。新的招股說明書補充文件允許在新的20,000,000美元限額內出售額外股份，其中包括通過銷售協議獲得的總收益。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息